T poietic cells are controlled by a number of growth factors that require coordinated regulation of their expression and of the expression of their receptors. The dysregulation of genes for hematopoietic growth factors and their receptors may be one of the events that leads to leukemogenesis through aberrant autocrine and paracrine growth mechanisms.' According to the autocrine growth model, the abnormal production of a growth factor by a cell, which also expresses functional receptors for that factor, releases the cell from normal growth control and may finally lead to malignant transformation. ' There is increasing evidence that supports the autocrine growth hypothesis. In murine IeLkemic cells, the expression of growth factor genes has been shown to be the result of the insertion of intracisternal A-particles or retroviruses into the promoter region of either interleukin-3 (IL-3), IL-6, or granulocyte-monocyte colony-stimulating factors (GM-CSF) genes, resulting in constitutive growth factor Autocrine production of growth factors has also been shown recently in several human hematologic malignan~ies.~.'~ It is also reasonable to expect that if these malignancies respond to endogenous production of a specific cytokine, they will 0 1993 by The American Society of Hematology.
0006-4 9 71/93/8 I I I -0036$3.00/0
formation when the cells were seeded at low density; G2 cells constitutively expressed mRNA for GM-CSF and GM-CSF receptor; G2 cells also produced and secreted measurable amounts of GM-CSF into cell culture supernatant; and, monoclonal anti-GM-CSF antibodies abolished 62 colony growth when added to cultures with cells seeded at low density without growth factors. Of the other four ALL cell lines, three expressed mRNA for GM-CSF receptor and responded in vitro to added GM-CSF with increased blast colony growth; however, none of these four cell lines expressed mRNA for constitutive production of GM-CSF. A fifth ALL cell line lacked receptors for GM-CSF and did not respond in clonogenic assays to added GM-CSF. Thus, a bioregulator of normal hematopoiesis plays a central role in autocrine growth control of G2 ALL cells, and an important paracrine growth-promoting role in three of four other ALL cell lines. also show a paracrine growth response to exogenous cytokine produced by adjacent cells of different lineage.
Little information is available about the possible role of autocrine or paracrine growth in B-lineage acute lymphoblastic leukemia (ALL) in humans. We have previously shown IL-1-mediated autocrine growth in a biphenotypic ALL cell line. 6 We now report the existence of a GM-CSF-mediated autocrine cycle in another ALL cell line of pre-B phenotype, and the positive growth response of three additional ALL lines to exogenous GM-CSF.
MATERIALS AND METHODS
Primary cells and ALL cell lines. Primary cells were obtained from bone marrow aspirates taken from 19 newly diagnosed or relapsed children with pre-B ALL. Five lines were established from additional patients and were termed A 1, B 1, C 1, G2, and W 1, respectively. These studies were approved by the Intemal Review Board in our institution.
B1,6 and G224,25 lines were derived from freshly obtained peripheral blood composed primarily of blast cells from two children with B-lineage ALL. C1 was established from the diagnostic marrow sample from a child with B-lineage ALL. W I was derived from bone marrow cells from a child with Juvenile chronic myelogenous leukemia in lymphoid blast crisis.26
Leukemic cells were isolated from the specimens by Percoll (Pharmacia, Piscataway, NJ) density gradient centrifugation and cultured with weekly medium changes in 25-cm2 tissue culture flasks (Coming Glass Works, Corning, NY) in a-modified minimum essential medium (MEM; GIBCO, Grand Island, NY) containing 10% heat-inactivated fetal bovine serum (FBS Flow, McLean, VA). Medium was changed weekly and cultures were incubated at 37°C in a humidified incubator with 5% C 0 2 and 95% ambient air. After 6 weeks, the cells from all five specimens grew as a single-cell suspension.
The G2 cells were thenckoned in semi-solid methyl cellulose (0.9% Methocel; Dow Chemical Co, Midland, MI). The cloned cell line maintained the immunologic markers of the original leukemic blasts derived from the blood specimens at the time of relapse. Cells from the other four lines were studied directly from the suspension cultures without the cloning step performed on G2 cells.
The characterization studies of the lines were as follows. All were free of mycoplasma and Epstein-Barr virus (EBV) and grew autonomously. The phenotype of AI cellsz4 maintained in culture was For personal use only. on October 25, 2017 . by guest www.bloodjournal.org From
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HLA-DR+, CD19+, CD20-, and CD10-although the original relapse sample was CD10+. No cytoplasmic or surface p was detected; one rearranged and one germline p chain gene and nonrearranged light chain genes were observed. The karyotype of the A1 line was essentially 46,xy, but with multiple structural and numerical abnormalities.
The B1 line was characterized by a t(4;ll) (q21;q23) chromosomal translocation and biphenotypic features of early B and myeloid lineages. 6 The phenotype ofthe C l cell line was HLA-DR+, CD19+, CD19+, and CD20-. The karyotype showed 46,xy/47,xy, -1, der(7), der( 12), +MI, f M 2 .
The phenotype of the G2 cell line24s25 was HLA-DR+, CD19+, CD20-, and CD10-, although the original patient sample contained 40% cells expressing low levels of the CDlO antigen. The karyotype of the G2 line was as follows: 46,XX, der(5), t(5;?), (q15;?), der(9), t(9:?), (p13:?), -1 1, der(l4), t(14;?), (q22;?), f M 1 , with variations.
The phenotype of the W1 cell line was HLA-DR', CD10+, CD19+, and CD20-. The karyotype analysis showed monosomy 7 (45,xy,-7). Ig heavy chain DNA rearrangement for 1 allele was observed.
Clonogenic assays were performed on freshly obtained bone marrow samples from the 19 newly patients with ALL to determine the effect of GM-CSF on blast colony formation.
The ALL blast colony assay was performed as described.27 Briefly, after a Percoll fractionation, T-cell-depleted bone marrow cells (2 X lo5) were suspended in a-medium, 10% FBS, 10% phytohemagglutinin (PHA)-conditioned medium, irradiated autologous leukemic blasts used as feeder cells ( 105/mL), and methylcellulose at a final concentration of 0.9% (vol/vol) in 35-mm Petri dishes.
In selected patients (indicated in Results), the marrow specimens were enriched further for lymphoblasts before plating by using immunomagnetic f r a c t i~n a t i o n .~~*~~ With this procedure, ALL blasts were specifically isolated from the marrow mononuclear cell fraction using magnetic Dynabeads coated with CD 10 and/or CD 19 with a Dynal MPC magnet (Dynal, Inc, Great Neck, NY). The resulting cell population was composed of 99% lymphoblasts.
The culture dishes were placed in 37°C with 5% C 0 2 in air in a humidified atmosphere. On days 3 to 5 of incubation, the colonies were counted. A cluster of more than 20 cells was defined as a colony. Individual colonies were plucked from the culture plates with a micropipet and smeared on glass slides for further evaluation with use of Wright's stain. For control, 2 X IO5 irradiated feeder cells were cultured alone in the same assay system in each experiment to exclude their potential for colony formation.
The colonies were confirmed as originating from the original leukemic blast population by surface marker analysis and cytogenetic studies, as detailed previously.27
Clonogenic assays were also performed on the ALL cell lines in semi-solid medium. The cell lines, at the indicated density, were plated in 35-mm Lux suspension dishes (Nunc, Inc, Naperville, IL) in amedium containing 10% FBS in methylcellulose. Duplicate culture dishes were incubated at 37°C with 5% C02 in air in a humidified atmosphere. Colonies (220 cells) were counted after 8 days using an inverted microscope.
When serum-free conditions were required, the improved medium described by Correa and Axelrad3' was used.
Detection of GM-CSF, tumor necrosis factor-a (TNF-a), and IL-1 receptors byjow cytometry. The percentage of cells bearing GM-CSF receptors and receptors for TNF-a and for IL-1 was determined by flow cytometry using Fluorkine reagents (R and D Systems, Minneapolis, MN) composed of GM-CSF, TNF-a, and I L 1 all conjugated directly with phycoerythrin. Isotype-matched controls were used to subtract background binding. There always was correlation between GM-CSF receptor expression by flow cytometry and GM-CSF-re-
Clonogenic assays.
sponsive leukemia cell samples. Samples that did not express GM-CSF receptors did not show a growth response to GM-CSF.
Quantitation of mRNA of cytokines and cytokine receptors by the polymerase chain reaction (PCR).
The quantitation of specific mRNA species by PCR was performed using synthetic DNA as an internal standard, as previously described." The technique involves coamplification of a target cDNA (produced from the corresponding mRNA by reverse transcription) and of the internal standard. The target cDNA and the internal standard use the same primer sequences but yield PCR products of different sizes that can be separated by gel electrophoresis. Total cellular RNA was prepared according to the methods of Chomczynski and Sa~chi.~' RNA concentrations were measured spectrophotometrically (Beckman Instruments DU-40; Beckman Instruments, Fullerton, CA). The integrity ofthe RNA was confirmed by electrophoresis under denaturing conditions on a 1% agarose gel.
cDNA was prepared by reverse transcription at 37°C for 60 minutes in a 20 pL reaction mixture containing 2 pg of total cellular RNA, 1 mmol/L dithiothreitol, 0.5 mmol/L dNTP, 0.1 pmol of a specific oligonucleotide primer, and 100 U of recombinant Moloney's murine leukemia virus (MMLV) reverse transcriptase (Bethesda Research Laboratories, Gaithersburg, MD). Internal standard DNA (0.1 to 3.0 pg) and cDNA (produced from 100 to 300 ng total cell RNA) were amplified together with 1 U of Thermus aquaticus DNA polymerase (Taq polymerase; Perkin-Elmer/Cetus, Norwalk, CT) and 50 mmol/ L dNTP, and 0.1 mmol/L each of the 5' and 3' primers (1 X lo6 cpm of y3' P-end-labeled primer was added where indicated) in a total volume of 50 pL. The mixture was overlaid with mineral oil and then amplified using a thermal cycler (Ericomp, San Diego, CA) over a number of cycles (indicated in text) consisting of denaturing at 95°C for 30 seconds, primer annealing at 54°C for 30 seconds, and extending at 72°C for I minute. Ten microliters of PCR product was electrophoresed using 8% polyacrylamide gels in Tris borate/EDTA buffer. Gels were stained with ethidium bromide and photographed.
Cytokines, antibodies, and enzyme-linked immunosorbent assay (ELISA). Recombinant human IG l a (rhIL-1 CY; specific activity, 3 X 10' U/mg) was a gift from Hoffmann-La Roche (Nutley, NJ); rhIL-2 (3 X lo6 U/mg protein) was purchased from Genzyme Co (Boston, MA); rhIL-3 (6 X lo6 U/mg), rhIL-4 (1.2 X lo4 U/mg), rhlL-5 (1.2 X lo3 U/mg), rhIL-6 (4 X lo6 U/mg), rhIL-7 (3 X lo3 U/mg), rhGM-CSF (10.6 X lo6 U/mg), and recombinant human granulocyte-CSF (rhG-CSF) (3 X lo4 U/mL) were gifts from the Genetics Institute (Cambridge, MA); recombinant human stem cell (steel) factor (1 X lo5 ng/mL) was donated by Immunex (Seattle, WA); rhTNF-a (5.6 X IO7 U/mg) was donated by Genentech, Inc (South San Francisco, CA); interferon-7 (IFN-y; 1 X lo7 U/mg) was a gift from Biogen (Cambridge, MA).
Purified murine monoclonal antirecombinant human GM-CSF (HGM2/3.1) was obtained from the Genetics Institute. In a CML bioassay system, 10 pg/mL of anti-GM-CSF completely neutralized 5 U/mL of rhGM-CSF. Antihuman TNF-a (Genentech, Inc) had a neutralization titer of greater than 5 X lo5 neutralizing units/mL when tested in a mouse LM cell cytolysis bioassay. With antihuman I L 3 (Genetics Institute), 350 ng neutralized 8 U of IL-3.
Antibodies used in flow cytometry experiments were purchased from Coulter (Hialeah, FL) as rhodamine conjugates for B4-IgG and T3-IgG, and fluorescein isothiocyanate (FITC) conjugates for My9-IgG, My4-IgG, and T3-IgG. An ELISA specific for GM-CSF was performed by Dr Kenneth Grabstein (Immunex, Seattle, WA). Sensitivity of the assay was shown to be 4 pg/mL.
Statistical analysis of the data was performed using the Student's t-test, and differences were expressed by P values.
Statistics.
For personal use only. on October 25, 2017. by guest www.bloodjournal.org From A growth response to GM-CSF 5 U/mL was arbitrarily defined as a 50% increase or higher in blast colony numbers compared with cultures lacking GM-CSF. The "questionable responders" had either baseline colony counts that were too low or "responding" colony counts that were not high enough to allow a confident interpretation. Patients no. 2, 7, 10, and 15 were in bone marrow relapse at time of study; the others were newly diagnosed patients. All specimens were initially fractionated on a Percoll gradient. Specimens from patients no. 7, 10, and 17 were further enriched for blasts by Dynabead fractionation before culture; the others were cultured directly (see Materials and Methods).
Values shown are the mean of duplicate cultures.
RESULTS
Studies on freshly obtained ALL blast cells.
Freshly obtained marrow samples from 19 newly diagnosed or relapsed patients with ALL were studied in blast colony assays to determine the effect of added GM-CSF (Table l) . In these studies, a growth response to GM-CSF was arbitrarily defined as a 50% increase or higher in ALL blast colony numbers compared with cultures lacking GM-CSF.
In 7 of the 19 marrow samples, a clear-cut increase in blast colonies was seen in cultures containing GM-CSF at 5 U/ mL. Some of the increases were striking (eg, the 8-fold and IO-fold increases in blast colonies observed with samples from patients no. 1 and 2, respectively). There were four further samples (patients no. 8 through 1 1, Table 1 ) that also appeared to show a response to GM-CSF, but they were placed in a "questionable" category because either the baseline colony counts were too low or "responding" colony counts were not high enough to allow a confident interpretation.
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Overall, in the GM-CSF-responsive group of 7, there was an average increase in blast colonies of 346% (range, 50% to 1,000%) in cultures containing the cytokine. Because the marrow samples were highly enriched for blast cells before plating, especially in samples from patient no. 7 that were fractionated by immunomagnetic beads yielding greater than 99% blasts, the target cells for GM-CSF were almost certainly the leukemia population and not accessory cells.
After immunomagnetic bead fractionation, the ALL blast population from patient no. 7 was chosen for analysis by flow cytometry to determine the percentage of cells bearing GM-CSF receptors (Fig I) . The results clearly indicated GM-CSF receptor expression in 38% of blast cells from patient no. 7 that were functionally active judging from the GM-CSF growth response shown in Table 1 .
These findings indicated that ALL blasts from some patients express GM-CSF receptors and proliferate in vitro in response to added GM-CSF. The data prompted us to study the ALL cell lines in detail with respect to cytokine growth control.
The G2 cell line exhibited density-dependent growth in a serum-free clonogenic assay system without added growth factors. No growth was observed at cell concentrations below 1.4 X lo5 cells/ mL, whereas at higher cell concentrations colony formation did occur (Fig 2) . It was also observed that medium harvested from cultures of G2 cells grown at high density in suspension stimulated the formation of colonies of G2 cells seeded in serum-free medium at a low density of 1.5 X lo5 cells/mL (data not shown). These observations are consistent with autocrine growth control of G2 cells.
Effects of exogenous cytokines on G2 colony formation.
To identify the cytokines that may be involved with growth regulation of G2 cells, the effect of various cytokines was tested on colony formation (Fig 3) . Of 10 cytokines tested, Autocrine growth regulation of G2 cells. GM-CSF, IL-3, IL-6, and IL-7 significantly stimulated colony formation of G2 cells above baseline values in control cultures lacking cytokine or growth factors (P values for studies with IL-6 and with IL-3 are <.O I and <.OOO I , respectively). Three other cytokines, IL-4, TNF-a, and IFN-7. inhibited the formation of G2 colonies, whereas IL-I, IL-5, and stem cell factor (SCF) had no effect on the growth of G2 cells. Harvested supernatant from G2 cells grown at high density in liquid cultures stimulated the formation of colonies in a serum-free assay of G2 cells seeded at 1.5 X IO5 cells/mL (P < .Ol), suggesting the production and secretion of autocrine growth factor(s) by G2 cells grown at high density. Growth (percent change) The internal standard DNA gives rise in each case to a predicted PCR product of -250 bp, whereas the same primers amplify PCR products of -350 to 370 bp for individual cytokine cDNAs. PCR products of individual cytokines were electrophoresed and stained with ethidium bromide as described in Materials and Methods.
Expression yf cytokine in RNAs and cytokine receptors by G2 cells. To identify a candidate cytokine(s) that was o p erative in the autocrine growth regulation of G2 cells, the repertoire of cytokine mRNAs expressed by the cell line was determined. For this, an internally controlled PCR assay with sequence-specific synthetic DNA as a positive control was used. The results (Fig 4) showed that of IO cytokines tested. G2 cells expressed mRNAs for 3 of them. IL-IP, TNF-a. and
Further studies for detection of cytokine receptors by PCR and by flow cytometry using florescein-labeled cytokines showed GM-CSF receptors on 96% of G2 cells (Fig 5) and TNF-a receptors, but no receptors for IL-l (data not shown).
GM-CSF.
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GM-CSFproduction by G2 cells and the efect of anti-GM-CSF antibody on G2 growth. Using specific ELISA, it could be shown that G2 cells produced and secreted GM-CSF into the culture media (mean k SD GM-CSF production from three cultures was 16.4 f 2.8 pg/mL compared with <1.0 pg/mL in control media). In a separate experiment designed to determine the effect of a 15 pg/mL concentration of GM-CSF on G2 colony growth, a 79% increase in colony numbers was observed (from 195 +-3 to 350 f 36 colonies/culture). Thus, G2 cells expressed mRNA for GM-CSF, constitutively produced the protein actively, and bore cell-surface receptors for GM-CSF.
Finally, to show a functional autocrine loop for GM-CSF, the effect of monoclonal anti-GM-CSF neutralizing antibody on the formation of G2 colonies was studied ( Table 2 , experiment A). Anti-GM-CSF antibody inhibited by 99% G2 colony growth that was stimulated by exogenous GM-CSF, and directly abolished "autonomous" G2 colony growth in cultures lacking an added source of GM-CSF. When the study was repeated using higher cell numbers in the cultures ( 1.3 X lo5 cells v 1. 1 X to5 cells plated), the growth-promoting effect from the increased cell density was more difficult to suppress with anti-GM-CSF antibody; nevertheless, a 65% inhibition was still observed on G2 colony growth stimulated by exogenous GM-CSF, and a 38% inhibition was seen on "autonomous" G2 colony growth. In separate experiments (Table 3) , neither anti-IL-3 antibody nor anti-TNF-a anti- 
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Values shown are means of duplicate cultures. In these studies, the dilution of anti-GM-CSF antibody was 1 /500, equivalent t o 10 pg/mL.
body had any effect on G2 colony growth. Similarly, anti-GM-CSF antibody had no effect on B1 colony growth. An additional experiment was designed to determine ifthe suppressive effect of anti-GM-CSF neutralizing antibody on G2 colony growth could be "overcome" by adding excess concentrations of GM-CSF (Table 2, experiment B) . Similar to data shown in experiment A, GM-CSF augmented G2 colony growth and anti-GM-CSF antibody suppressed G2 colony growth. However, when a 10-fold increase in GM-CSF was added to cultures containing anti-GM-CSF antibody, the inhibitory effect of the antibody was reversed. This indicates that the suppression induced by the antibody was trolled PCR assay with sequence-specific synthetic DNA for GM-CSF, none of the other three ALL cell lines (Al, C1, and W 1) expressed mRNA for GM-CSF. However, when all three cell lines were cultured with added GM-CSF ( 5 U/mL) and compared with cultures lacking GM-CSF (Table 4) , marked increments in blast colony numbers with GM-CSF were observed (P < .01 for all studies), indicating surface expression of functional GM-CSF receptors. In contrast to the four ALL cell lines that expressed receptors for GM-CSF and responded positively in clonogenic assays to added GM-CSF, the fifth ALL cell line, B1, did not express GM-CSF receptors and did not show growth augmentation in response to exogenous GM-CSF (data not shown).
DISCUSS ION
We established the human ALL cell lines to characterize the expression of cytokines and cytokine receptor genes in this disease. These studies were prompted by our finding that leukemic bone marrow samples from some patients with ALL responded in vitro to added GM-CSF with an increase in blast colony growth. Because not all of the marrow samples showed the GM-CSF response, there is clearly heterogeneity in this regard, which may partly explain why Touw et failed to see proliferative responses of ALL cells to recombinant cytokines.
A major objective of our current effort is to understand the mechanisms of leukemic cell growth in ALL and to identify the means to either promote cellular differentiation or restrict leukemic proliferation. Transient expression is a characteristic and critical feature of most cytokine genes. Cytokine mRNAs are usually undetectable until the cells are induced by appropriate stimuli.34 A notable exception to this rule is the constitutive expression of cytokine and cytokine receptor genes resulting in a growth-promoting autocrine loop in some transformed ~e l l s .~-'~ In general, aberrant expression of various growth factors and their receptors appears to play a role in cell transformation, often as a consequence of dysregulation of these One example is the constitutive expression of I L 2 and I L 2 receptor genes in human T-cell lymphotropic virus type 1 (HTLV-1)-infected adult T-cell leukemia. 13 In this situation, it was shown that distinct DNA sequences in the 5'-flanking region of the IL-2 receptor gene were responsive to transcriptional activation by the transacting HTLV-I product tat I. Another example is the aberrant activation and expression of the IL-3 gene seen in the chromosomal translocation t ( 5 ; 14) of B-lineage ALL.35,36 The possible role of transcriptional dysregulation of cytokine and cytokine receptor genes associated with autocrine loops in other phenotypes of ALL remains to be more fully explored.
In our study described here, we discovered that four of five ALL cell lines with diverse phenotypes and karyotypes expressed functional cell-surface receptors for GM-CSF, and responded with a brisk augmentation of blast colony growth when exposed to exogenous GM-CSF. These findings correspond with those of Lange et al,37 who determined that GM-CSF-dependent ALL cell lines can be established from some children with acute leukemia. Our fifth cell line studied, previously characterized6 as an ALL with biphenotypic features, did not express GM-CSF receptors and did not show a growth response to exogenous GM-CSF. Indeed, the growth of this line, termed B1, was shown to be dependent on the constitutive expression of IL-1 receptors and of I L 1 cytokine in an autocrine manner. Autocrine growth control, whereby a transformed cell elaborates a factor that supports its own growth, is an important concept that is emerging as a unifying theme in studies of the role of growth factors in m a l i g n a n~y .~,~~~~~ It has been suggested that endogenous production of polypeptide growth factors that act on their producer cells via external or even internal receptor sites could be responsible for malignant transformation of cells. This theme was further strengthened when it was discovered that the macrophage-CSF (M-CSF) receptor is encoded by the c-fms proto-oncogene'* and that the combination of c-fms and M-CSF had transforming activity through an autocrine m e~h a n i s m . '~~'~ Reports from Young et aIi5-l7 on a large number of freshly obtained human AML specimens indicated aberrant gene expression of dM-CSF by blast cells as well as the secretion of biologically active GM-CSF. In addition, an autocrine loop involving IL-1 has been reported with fresh AML blast cells* and another involving IL-7 with ALL c e k g Human multiple myeloma cells also have been shown to produce IL-6 with strong evidence of autocrine growth regulation." Moreover, leukemic cells from a patient with T-cell chronic lymphoblastic leukemia (CLL) expressed the genes for both IL-2 and the IL-2 receptor in a constitutive manner, and responded synergistically to exogenous IL-2." Also, B CLL and hairy cell leukemia produced and responded to IL-1,'8,i9 IL-6,20,2' and TNF.22,23 Thus, several hematologic malignancies may in fact possess an autocrine mechanism allowing continuous proliferation.
Our data on the G2 ALL cell line provided several lines of evidence that implicate the participation of GM-CSF in the autocrine growth regulation ofG2 cells. This phenomenon has not been reported previously in ALL, although neoplastic B CLL lymphocytes have been shown to produce GM-CSF. 40 For personal use only. on October 25, 2017 . by guest www.bloodjournal.org From
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Firstly, the growth of G2 cells in vitro was density dependent, and exogenous GM-CSF stimulated an increase in G2 colonies when the cells were seeded at low density. Secondly, G2 cells constitutively expressed the mRNA for GM-CSF and for GM-CSF receptor, and the cells produced and secreted measurable concentrations of GM-CSF. Finally, anti-GM-CSF antibodies abolished G2 colony growth directly when added to cultures of cells seeded at low density, and inhibited colony growth when seeded at higher density.
The autocnne pattern of growth of G2 cells contrasts sharply with the other three lines that responded to exogenous GM-CSF because none of the other three lines expressed mRNA for GM-CSF. The pattern of growth for the other three lines should be described more appropriately as paracnne.
Thus, the data from these studies indicate that a bioregulator of normal hematopoiesis plays a central role in the "autonomous" proliferation of one cell line, and exerts a strong growth-promoting effect on three others. For personal use only. on October 25, 2017 . by guest www.bloodjournal.org From
